Risk Factors Update Summary
- Humira faces significant decline in revenues following loss of exclusivity in 2023.
- The Inflation Reduction Act may lead to government-set prices for certain drugs starting in 2026.
- AbbVie faces potential revenue erosion and accelerated intellectual property expiration due to price-setting.
- Changes in U.S. tax laws now require a 15% alternative minimum tax on net stock repurchases.
- AbbVie's vulnerability to cybersecurity attacks poses risks of data breaches and potential substantial costs.
- AbbVie's intangible assets decreased, with developed product rights at $55 billion and goodwill at $3 billion.
- AbbVie's compensation committee anticipates granting additional stock options under employee benefits plans.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1551152&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.